Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Completed · Phase 2

Conditions studied: Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma

In brief

Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free survival at one year after transplant compared to the current standard prophylaxis regimen.

Key facts

Study ID: NCT02208037
Run by: National Heart, Lung, and Blood Institute (NHLBI)
People needed: 279
Starts: 2014-08-01
Expected to finish: 2017-10-01
Last updated by the study team: 2019-01-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Age 18-75 years (patient is older than 18.0 and less than 76.0 years old)
Patients with acute leukemia, chronic myelogenous leukemia or myelodysplasia with no circulating blasts and with less than 5% blasts in the bone marrow.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular, marginal zone, diffuse large B-cell, Hodgkin's Lymphoma,or mantle cell lymphoma with chemosensitive disease at time of transplantation
Planned reduced intensity conditioning regimen (see eligible regimens in Table 2.4a)
Patients must have a related or unrelated peripheral blood stem cell donor as follows:
Sibling donor must be a 6/6 match for HLA-A and -B at intermediate (or higher) resolution, and -DRB1 at high resolution using DNA-based typing, and must be willing to donate peripheral blood stem cells and meet institutional criteria for donation.
Unrelated donor must be a 7/8 or 8/8 match at HLA-A, -B, -C and -DRB1 at high resolution using DNA-based typing. Unrelated donor must be willing to donate peripheral blood stem cells and be medically cleared to donate stem cells according to National Marrow Donor Program (NMDP) criteria.
Cardiac function: Ejection fraction at rest ≥ 45%
Estimated creatinine clearance greater than 50 mL/minute (using the Cockcroft-Gault formula and actual body weight)
Pulmonary function: Diffusing capacity of the lung for carbon monoxide (DLCO) ≥ 40% (adjusted for hemoglobin) and forced expiratory volume in one second (FEV1) ≥ 50%
Liver function: total bilirubin < 1.5 x the upper limit of normal and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5x the upper normal limit. Patients who have been diagnosed with Gilbert's Disease are allowed to exceed the defined bilirubin value of 1.5x the upper limit of normal.
Female subjects (unless postmenopausal for at least 1 year before the screening visit, or surgically sterilized), agree to practice two (2) effective methods of contraception at the same time, or agree to completely abstain from heterosexual intercourse, from the time of signing the informed consent through 12 months post transplant (see Section 2.6.4 for definition of postmenopausal).
Male subjects (even if surgically sterilized), of partners of women of childbearing potential must agree to one of the following: practice effective barrier contraception (see Section 2.6.4 for list of barrier methods), or abstain from heterosexual intercourse from the time of signing the informed consent through 12 months post transplant.
Signed informed consent

You may not qualify if…

Prior allogeneic transplant
Karnofsky Performance Score < 70%
Active central nervous system (CNS) involvement by malignant cells
Patients with uncontrolled bacterial, viral or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.
Presence of fluid collection (ascites, pleural or pericardial effusion) that interferes with methotrexate clearance or makes methotrexate use contraindicated
Patients with transformed lymphoma (e.g., Richters transformation arising in follicular lymphoma or chronic lymphocytic leukemia)
Patients seropositive for the human immunodeficiency virus (HIV)
Patient with active Hepatitis B or C determined by serology and/or nucleic acid amplification tests (NAAT)
Patients with hypersensitivity to bortezomib, boron or mannitol
Patients with ≥ grade 2 sensory peripheral neuropathy
Myocardial infarction within 6 months prior to enrollment or New York Heart Association (NYHA) Class III or IV heart failure (see Appendix D), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening must be documented by the investigator as not medically relevant.
Female patients who are lactating or pregnant
Patients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study
Patients with prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent ≥ 5 years previously will be allowed. Cancer treated with curative intent < 5 years previously will not be allowed unless approved by the Protocol Officer or one of the Protocol Chairs.
Planned use of anti-thymocyte globulin (ATG) or alemtuzumab in conditioning regimen.
Planned post-transplant therapy, including use of tyrosine-kinase inhibitors (TKI).
Inability to withhold agents that may interact with hepatic cytochrome P450 enzymes (CYP3A4), or glutathione S-transferases involved in bortezomib and/or busulfan metabolism during day -5 through day +7. It is acceptable to use alternative non-interacting medications during this period, and then resume prior medications.
Patients with secondary acute myeloid leukemia arising from myeloproliferative disease, including Chronic myelomonocytic leukemia (CMML), with evidence of active myeloproliferative features or myelofibrosis in the background.

Where it is running

City of Hope National Medical Center — Duarte, California, United States
Stanford Hospital and Clinics — Stanford, California, United States
University of Florida College of Medicine (Shands) — Gainesville, Florida, United States
H. Lee Moffitt Cancer Center — Tampa, Florida, United States
Emory University — Atlanta, Georgia, United States
BMT Program at Northside Hospital — Atlanta, Georgia, United States
Loyola University Medical Center — Maywood, Illinois, United States
University of Iowa Hospitals and Clinics — Iowa City, Iowa, United States
University of Kansas Hospital — Westwood, Kansas, United States
Johns Hopkins University — Baltimore, Maryland, United States
Dana Farber Cancer Institute/Massachusetts General Hospital — Boston, Massachusetts, United States
Dana Farber Cancer Institute/Brigham & Women's — Boston, Massachusetts, United States
Karmanos Cancer Institute/BMT — Detroit, Michigan, United States
University of Minnesota — Minneapolis, Minnesota, United States
Mayo Clinic - Rochester — Rochester, Minnesota, United States
Washington University/Barnes Jewish Hospital — St Louis, Missouri, United States
University of Nebraska Medical Center — Omaha, Nebraska, United States
Roswell Park Cancer Institute — Buffalo, New York, United States
Memorial Sloan-Kettering Cancer Center — Manhattan, New York, United States
University of North Carolina Hospital at Chapel Hill — Chapel Hill, North Carolina, United States
Cleveland Clinic Foundation — Cleveland, Ohio, United States
University Hospitals of Cleveland/Case Western — Cleveland, Ohio, United States
Ohio State/Arthur G. James Cancer Hospital — Columbus, Ohio, United States
Oregon Health & Science University — Portland, Oregon, United States
University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.